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Abstract  
 
The goal of this paper is to provide an updated review for scientists and clinicians on the major areas in 
cardiovascular medicine published in the Journal. Leading topics in regenerative and personalized medicine are 
presented along with a critical overview of the field. New standards in large preclinical animal models of 
pulmonary hypertension and left bundle branch block are highlighted. Finally, clinical care in the area of 
atherosclerosis, the aortic valve, platelet biology, and myocarditis is discussed as well as autonomic modulation 
therapies 
 
 
Regenerative Medicine 
 
Following myocardial infarction, the heart loses millions of cardiomyocytes. Because the heart has a limited 
regenerative capacity, the lost cells are not replaced by all new myocytes but with scar, composed of 
extracellular matrix. Although the scar prevents cardiac rupture and is initially beneficial, the 
high pressure in the left ventricle causes the infarct to expand  progressively, remodeling the heart and leading to 
heart failure [1]. In the last few years, different approaches have been developed to regenerate the injured 
myocardium, including administration of bone marrow stem/progenitor cells, adipose stem cells, induced 
pluripotent stem cell-derived cardiomyocytes sometimes combined with immunosuppressants, fibroblasts 
reprogrammed into cardiomyocytes, and noncoding RNAs [2–7]. Interestingly, an endogenous cell population 
with cardiomyocyte progenitor properties (cardiac progenitor cells, CPCs) has been recently described in the 
heart [8]. Although CPCs lack sufficient potential to regenerate the damaged myocardium on their own, 
administration of certain growth factors during the acute phase in the response to infarction can activate these 
cells, improving their cardiogenic potential [9]. Last year, Koudstaal and colleagues showed that this same 
approach is successful in a preclinical pig model of chronic myocardial infarction in which adverse cardiac 
remodeling is already taking place [10]. This group provides new evidence that injection of insulin-like growth 
factor-1 (IGF-1) and hepatocyte growth factor (HGF) as late as 4 weeks post-infarction improved cardiac 
contractility, especially when combined with UPy hydrogel. Administration of these factors increased the 
number of CPCs in the infarct region and resulted in improved angiogenesis, reduced cardiomyocyte 
hypertrophy, and reduced fibrosis. Furthermore, IGF-1 and HGF increased the cardiomyogenic potential of 
CPCs and the number of cardiomyocytes positive for Ki-67 [10]. Together, these results highlight the potential 
of therapeutic approaches based on the combination of growth factors and biomaterials to promote an integrative 
regenerative response that includes myocardial regeneration, improved angiogenesis, and reduced cardiac 
remodeling after myocardial infarction. These findings are especially relevant in a chronic ischemic setting like 
the one tested here [10].  
 
Personalized Medicine (Genomics and Electronic Health Records)  
 
Technology and Validation 
The development of next generation sequencing technologies is rapidly advancing the discovery of gene 
variants associated with cardiovascular disease [11]. This has been particularly relevant for the identification of 
variants underlying cardiac arrhythmias [12]. However, the cost associated with the analysis of a large number 
of samples is still a disadvantage. Pooling samples together has emerged as an alternative to individual 
sequencing to reduce the overall cost. However, this approach has the main disadvantage of diluting the 
mutation that one patient may have wild type alleles from all other patients, making it undetectable by DNA 
sequencing. Interestingly, in 2014, Juan Gómez and colleagues developed a protocol that allows sensitive 
identification of gene variants from pooled samples [13]. The authors focused on the following DNAvariants in 
genes associated with long QTsyndrome or Brugada syndrome: SCN5A, KCNH2, KCNQ1, KCNE1, and 
KCNE2. They sequenced the exon-coding sequence of these genes in 20 patients, each of whom was 
heterozygous for a different variant. Variants had already been determined in these patients by Sanger 
sequencing. The authors were able to detect up to 16 out of the 20 known variants, with four nondetected 
variants being present in PCR amplicons that were covered by no reads and mapped to DNA regions with high 
GC content. This new protocol opens a new avenue for rapid screening of known DNA variants in large patient 
cohorts without the need for barcoding and with a considerable reduction in cost. 
 
Coronary artery disease remains the leading cause of morbidity and mortality developed in developing 
countries. The early identification of coronary atherosclerosis may contribute to better stratification and 
preventive optimization of individuals at risk. Early detection and risk prediction typically relies on the 
traditional risk profiling or image-based early detection. Daniels et al. report on the value of a gene expression 
score (GES) in predicting obstructive coronary artery disease [14]. The utility of RNA (gene expression) as 
biomarkers used by clinicians to predict the likelihood of a clinical event in patients with coronary artery disease 
or clinical events in transplant patients or rejection in transplant patients has been relatively slow to replace 
standard imaging, stress testing, or biopsies [15]. The field of RNA biomarkers has lacked longterm studies on 
biological variation in stored samples on gene expression, and the effects of cardiovascular medication on gene 
expression and the effects of ethnicity on gene expression. These issues were all addressed in a large cohort of 
1500 subjects in an expansion of the PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary 
Tree) cohort [14]. The major findings were that expansion to 1500 individuals replicated the previous data, the 
relatively small nonwhite population (n=138) showed similar performance on the test as the whites, the stability 
of the blood samples over 5 years was good in 501 samples tested (i.e., no significant change in test 
performance between original set and most recent data), and finally, in the same 501 subjects, a small change in 
gene expression score was noted when a new blood sample was taken 5 years post and compared to the original 
sample [14]. Overall, this is important methodological data for the field moving forward. 
 
 
Lipids 
 
Different fat components absorbed in the intestine are transported in the blood by small particles that are 
composed of high, low and very low-density lipoproteins (HDL, LDL, VLDL), and apolipoproteins B and E 
(APOB, APOE). APOE and APOB are ligands for the LDL and VLDL receptors and are involved in 
cholesterol, vitamin, and lipoprotein transport and clearance. Lack of APOE results in accumulation of 
cholesterol and triglycerides in the blood, and APOE knockout mice fed with a high fat diet have been 
extensively used as a model of atherosclerosis in basic and preclinical research [16]. APOE is a polymorphic 
gene and each of its three forms (ε1, ε2, ε3) encodes an APOE isoform(APOE2, APOE3, APOE4) with varying 
affinity for LDL and VLDL receptors. Each individual can have up to two different isoforms, one for each of the 
two APOE alleles. Patients homozygous for ε3 or ε4 have increased LDL levels and are at a higher risk of 
developing coronary heart disease. A recent controversy has arisen with regard to the response of ε4/ε4 carriers 
to omega-3 fatty acids and its potential benefits, with one report suggesting a proatherogenic effect of omega-3 
acids in these patients and another one reporting an increase in LDL-cholesterol (LDL-C), compared to ε3 
homozygotes. In 2014,William S. Harris and colleagues carried out a study with 136,701 patients to confirm or 
refute this hypothesis [17]. They found no adverse interaction between the omega-3 index (percentage of 
eicosapentaenoic acid and docosahexaenoic acid over total fatty acids in blood) and the APOE genotype for 
LDL-C, APOB, and LDL particle number. Importantly, the distribution of APOE genotypes in the studied 
cohort matched that of the general population, indicating that the observations can be extended to the general 
population. The results obtained in this study are key to understanding the effects of omega-3 fatty acids on the 
concentration of lipoproteins and cholesterol in the blood. They confirm a favorable relationship between the 
omega-3 index and cardiovascular risk and put an end to the controversy of the negative effect of omega-3 fatty 
acids on patients with an APOE4 homozygous genotype.  
 
 
Electronic Health Records 
 
The emerging importance of electronic health records (EHRs) in translational cardiovascular research generally 
[18] and more specifically in genomics [19] was clearly highlighted in two excellent reviews in the Journal in 
2014. EHRs are playing an important role in clinical care but are now more fully recognized for their added 
value in translational by offering better access to big data. Among many issues discussed is the importance of 
adopting unified systems of recording information thereby allowing better integration of data—and this can 
present significant challenges where the data in question may range from structured, discrete datasets through to 
MRI imaging and even video recording. Key to the success of this overall approach is the adoption of common 
coding terminology. Current efforts toward an integrated EHR approach have also pointed the way forward as, 
for example, with the electronic and Medical Records and Genomics (eMERGE) consortium of US centers 
which has developed publically available EHR-based phenotype algorithms, the Electronic Healthcare Record 
for Clinical Research (EHR4CR) project which is highlighted for having produced a technical infrastructure to 
assist with integrating disparate EHRs, and the UK-based CALIBER project derived from EHRs and disease 
registries. It will be of interest to see how these issues play outmoving forward and how contrasting healthcare 
systems may offer complimentary advantages and disadvantages in terms of data collection. The effective 
capture of unstructured information and the use of data mining tools such as IBM Watson Analytics and SAS 
Context Categorization tools, which make use of natural language processing and machine learning techniques 
to drive hypothesis generation, are garnering the majority of attention in this field. Progress has been made in 
utilizing the EHRs for research and personalized medicine, yet much work remains. 
 Aortic Valve 
 
The Journal published a detailed review of molecular and mechanical interactions in the aortic valve and aorta 
by Krishnamurthy et al. [20]. Over the past two decades, extensive genetic investigation by several groups 
around the world led to the discovery of mutations in genes encoding components of the aortic extracellular 
matrix, the smooth muscle sarcomere, and factors involving TGF-beta and notch signaling that lead to familial 
aortic aneurysms. [21, 22] as the authors of this review point out, successful application of novel therapeutics 
for aortic aneurysm requires understanding not only of the genetic basis but also the biomechanical processes 
influencing aortic development and homeostasis. Their review includes the complex interplay among valve 
interstitial cells, valve endothelial cells, extracellular components of the aortic wall, and proteoglycans and 
glycosaminoglycans, all of which may influence aortic development and disease [20, 23, 24].  
 
There is considerable debate regarding the role of abnormal hemodynamic stress imparted by bicuspid aortic 
valves, with or without stenosis, on the development of thoracic aortic aneurysms [25]. The influence of 
biomechanical stress affects the aortic valve and the aortic wall differently, as the authors acknowledge in this 
review. They also describe the variability of hemodynamic stress throughout the aorta. While the traditional 
teaching of bicuspid aortic valve-associated turbulence causing aortic aneurysm cannot sufficiently explain 
aortic aneurysm in this setting, the role of abnormal hemodynamic flow and variation in shear stress remains 
under-studied in aortic disease pathogenesis [26, 27]. Other notable features of this review include a 
comprehensive summary of murine models of isolated or overlapping phenotypes with aortic valve disease and 
aortopathy, computational modeling of mechanobiology affecting the aortic valve and aorta, as well as the 
evolution of aortic prostheses and surgeries [20].  
 
 
Atherosclerosis 
 
Atherosclerosis is a systemic disease with a long asymptomatic phase where atherosclerotic plaques are 
generated in all vascular territories. Only when a cardiovascular complication suddenly occurs (such as 
myocardial infarction, and stroke) the disease is recognized. Treatment of the disease after symptoms appear 
represents a burden to healthcare systems and to individuals. An excellent and comprehensive review on 
detection strategies for subclinical atherosclerosis and assessment of progression and regression shed new light 
on a controversial area [28]. Fernández-Friera et al. include discussions of the current guidelines as well as 
global cost-effectiveness [28]. Coronary artery   calcium scoring rather than carotid intima-media thickness is 
emerging as the most useful clinical approach for improving risk assessment among asymptomatic subjects with 
intermediate risk. Further development of CT-based imaging with functional evaluation using either SPECT or 
algorithm-based assessment of fractional flow reserve may help further advance its clinical use, thanks to the 
comprehensive noninvasive assessment of the obstructive coronary artery disease. Molecular imaging 
technology holds the experimental promise for plaque detection and characterization but is not ready for the 
routine clinical use. The major conclusions reached were that atherosclerotic plaques detection by multi-
vascular ultrasound, coronary calcium quantification by computed tomography, and metabolic assessment of 
existing plaques by hybrid positron emission tomography/magnetic resonance imaging (PET/MR) will become 
part of the diagnostic package for assessing risk. Identification, quantification, and evaluation of metabolic 
status of atherosclerosis could help the design of preventive strategies if able to tackle these global epidemics. 
At the current time, no consensus has been reached on the usefulness of imaging for subclinical atherosclerosis. 
However, the field has determined that carotid IMT is no longer recommended for routine clinical assessment, 
and that coronary artery calcium is a useful diagnostic approach for those at intermediate risk [29]. The ongoing 
Bioimage [30] and Progression of Early Subclinical Atherosclerosis (PESA) [31] studies among others will tell 
whether this prediction holds true.  
 
 
Characterization of New Preclinical Models  
 
Pulmonary hypertension leads to high morbidity and mortality throughout the world [32]. Postcapillary 
pulmonary hypertension is the most frequent form of pulmonary hypertension [32]. Large animal models of 
postcapillary pulmonary hypertension that fully recapitulate the disease have been lacking. Pereda and 
colleagues describe a porcine model of postcapillary pulmonary hypertension induced by nonrestrictive banding 
of both inferior pulmonary veins [33]. Characterization with right heart catheterization and magnetic resonance 
showed all banded animals developed pulmonary hypertension, decreased RVejection fraction, and increased 
RV end-systolic volume [33]. Histopathology showed increased lung weight and fibrosis. Pulmonary arteries 
exhibited increased intimal and medial thickness with increased fibrosis [33]. The development of this new 
model represents a giant step forward for the field. A clear example of the utility of this highly 
translationalmodel is the demonstration thatmagnetic resonance imaging can accurately quantify changes in 
pulmonary vascular resistances without the need of serial invasive procedures [34]. In addition, by using this 
same model, it has been recently demonstrated that magnetic resonance imaging T1mapping can identify RV 
early dysfunction in subjects with pulmonary hypertension [35], opening the door for early identification of 
failing RV in the context of pulmonary hypertension. Large animal models of left bundle branch block to test 
cardiac resynchronization therapies or other therapies to treat left bundle branch block have been rare. Rigol et 
al. described the first closed chest porcine model in the Journal [29]. The porcine model uses localized 
endocardial radiofrequency ablation along with high rate pacing to avoid ventricular fibrillation. Left bundle 
branch block induction was confirmed by widening of the QRS wave, along with additional specific alterations 
in ECG pattern concordant with left bundle branch block including prolongation of activation time [29]. 
 
Myocarditis and Heart Failure 
 
Five papers in the Special Issue on Myocarditis and Heart Failure in the Journal evaluated innate and adaptive 
immunity during experimental viral and bacterial inflammatory heart disease. Coxsackievirus B3 (CVB3) 
infection in mice is a wellestablished model for viral myocarditis and dilated cardiomyopathy 
sharing many characteristics with clinical myocarditis and dilated cardiomyopathy including the following: (1) a 
male bias to the disease, (2) evidence for autoimmunity to cardiac antigens, and (3) viral persistence in the heart 
resulting in chronic myocarditis and dilated cardiomyopathy (whereas viral clearance during the acute phase 
leads to disease resolution) [36]. CVB3 infection activates TLR3 which upregulates tissue factor expression and 
a hypercoagulative state [37]. Ventricular thrombi occur in both clinical and experimental myocarditis. 
Thrombin activates protease-activated receptor-1 (PAR-1), which promotes type 1 interferon and chemokine 
responses linking the coagulation and inflammation systems. Matrix metalloproteinases (MMPs) and the tissue 
inhibitors of matrix metalloproteinases (TIMPs) have crucial roles in myocarditis and dilated cardiomyopathy 
[38]. Specific MMPs and TIMPs are induced by CVB3 infection. MMP1 and MMP13 can activate PAR-1. 
Other MMPs promote leukocyte diapedesis. Apoptosis of cardiomyocytes is implicated in cardiac injury during 
ischemia and reperfusion injury. Autophagy, a cellular process allowing recycling of damaged organelles and 
cytosolic components, protects against apoptosis. Estrogens prevent apoptosis not only through increased 
expression of antiapoptotic molecules such as BCL2 family members but also through sex bias induction of 
autophagy [39]. Viruses use autophagosomes as platforms for replication, but autophagy also cross-presents 
endogenous antigens on major histocompatibility complex class II (MHCII) molecules. This pathway may be 
crucial in induction of autoimmunity, which is a major pathogenic factor in cardiac damage. Group A 
streptococcus, the cause of rheumatic heart disease [40], andCVB3 [36] both induce CD4+ Tcell responses 
which cross-reactively recognize microbial and heart antigens and can adoptively transfer myocarditis to naive 
recipients.  
 
 
Autonomic Modulation Therapies 
 
Heart failure is often characterized by changes in the autonomic nervous system, manifesting as an excess of 
sympathetic activity and a withdrawal of parasympathetic activity. This imbalance has been targeted 
traditionally with betaadrenergic blockade, renin-angiotensin-aldosterone system inhibitors, and exercise 
training. Device therapies, which electrically modulate the autonomic system, have also been proposed and were 
the focus of a series published in the Journal [41]. This series reviewed the physiological foundations for the 
therapies and highlighted the hurdles to translation into humans.  
 
Baroreflex activation therapy (BAT) targetsmechanosensitive sensory nerve fibers originating from the walls of 
the carotid sinuses. Edoardo Gronda et al. described the consequences of baroreflex dysfunction in heart failure 
and presented the scientific rational, preclinical evidence, and open-label clinical trial data that led to the first 
randomized trial investigating BAT in heart failure patients with reduced ejection fraction [42]. The HOPE4HF 
study (NCT01471860, NCT01720160) enrolled 146 patients and randomized them to BAT or guidelinedirected 
medical therapy [43]. BAT had a favorable safety and tolerability profile and when compared to the control 
group, BAT demonstrated significant improvements in NYHA classification, quality of life, and 6-min hall walk 
distance. This body of translational research sets the stage for an event-based trial.  
 
The first clinical studies of spinal cord stimulation (SCS) in class III systolic heart failure patients have 
produced mixed results. Hung-Fat Tse and colleagues enrolled 22 patients in the open-label multicenter SCS 
HEART trail (NCT01362725) and showed improvement over 6 months in a composite score of 6 efficacy 
parameters [44]. In contrast, it was reported at the 2014 American Heart Scientific Sessions that the single blind, 
randomized, controlled DEFEAT-HF trial which enrolled 81 patients (NCT01112579) failed to meet its primary 
and secondary efficacy endpoints at 6 months [45]. One possible explanation for the discrepant findings is that 
the stimulation location and intensity were not identical (i.e., continuous dual site stimulation at T1–T3 vs. 
intermittent single electrode stimulation at T2–T4, respectively). Although extrapolation should be done with 
caution, the results published by Lopshire and Zipes did demonstrate that the benefits of SCS, in an 
experimental heart failure model, are dependent on electrode location and stimulation intensity [46].  
 
Stimulation parameters may also be critical for the translation of vagal nerve stimulation (VNS) to heart failure 
patients. De Ferrari reviewed the preclinical and clinical evidence for VNS therapy and raised the dose issue, 
highlighting the complexity of many parameter combinations and calling for the evaluation of dose-response 
curves [47]. Incomplete understanding of this dose issue may have contributed to recent translational 
difficulties. Although significant improvements from baseline were found in left ventricular volume and ejection 
fraction in the open-label ANTHEM-HF clinical trial (NCT01823887), the randomized NECTAR-HF trial 
(NCT01385176) failed to demonstrate a difference, between groups, in remodeling [48, 49]. These results may 
be attributable to trial design, but might also reflect a difference in the dose delivered. ANTHEM-HF achieved a 
dose of 2 mA using 10 Hz, while NECTAR-HF delivered 1.2 mA at 20 Hz. Additional research is needed to 
identify appropriate doseresponse markers and optimizeVNS therapy delivery for heart failure patients. 
 
 
Invasive Cardiovascular Therapies 
 
The last few years have significantly pushed the frontier of invasive cardiovascular therapies forward. Treatment 
of valvular heart disease is becoming less invasive, particularly for higher risk patient subsets. Percutaneous 
approaches to previously untreatable coronary and peripheral vascular disease are now commonplace. Device 
therapies for stroke prevention in atrial fibrillation are reducing the need for anticoagulation in high-risk 
patients. And finally, novel stent platforms are emerging that may lead to improved percutaneous coronary 
intervention outcomes. Minimally Invasive Valve Therapies Multidisciplinary heart teams, including 
cardiologists, cardiac surgeons, anesthesiologists, and radiologists, have emerged as the state of the art in caring 
for patients with valvular heart disease and have resulted in optimization of patient care plans and outcomes. 
Landmark clinical trials such as the PARTNER and EVEREST trials have established the use of percutaneous 
approaches for the treatment of aortic stenosis and mitral regurgitation in patient populations with perceived 
high surgical risk. Concerns regarding increased stroke incidence compared to surgery, heart block requiring 
pacemaker, and paravalvular leaks have limited widespread adoption of percutaneous aortic valve therapies in 
lower risk populations. Smaller delivery systems and improved valve design strive to improve procedural safety 
and long-term efficacy [50]. Surgical valve therapies are becoming less invasive. Balloon expandable and self-
expanding aortic valves are being used surgically to avoid need for suture, thus, decreasing operating and 
cardiopulmonary bypass times. Development of minimally invasive approaches to surgical valve repair and 
replacement, such as the mini sternotomy and right sided thoracotomy approaches, has resulted in sternal 
sparing, a quicker return to activity and greater patient satisfaction. Pope et al. nicely describe in detail the 
performance and benefits of these cutting edge approaches to both aortic valve replacement and mitral valve 
repair [51].  
 
Percutaneous Treatment of Coronary and Peripheral Vascular Disease  
 
Chronic total occlusions (CTOs) are often referred to as the last frontier of percutaneous coronary intervention. 
With more effective medical therapies and more aggressive revascularization strategies, patients with coronary 
artery disease (CAD) are living longer. Due to this, CTOs are more common and present in 18.4 to 52 % of 
patients with CAD undergoing angiography. Advances in technique and equipment have resulted in successful 
antegrade and retrograde approaches to opening CTOs, resulting in anginal symptom improvement, increased 
exercise tolerance, improvement in left ventricular function, decreased need for more invasive coronary artery 
bypass grafting, and decreased mortality. Emmanouil Brilakis, one of the pioneers in this area, presents an 
excellent review of the techniques used in this constantly growing field [52]. Percutaneous approaches to critical 
limb ischemia have also seen great growth. Drug-eluting stent and balloon platforms have increased the success 
of intervention and decreased amputation rates. Endothelial progenitor cells and bone marrow mononuclear cells 
have shown promise in critical limb ischemia in small trials but larger trials are still needed to establish this 
therapy as effective [53].  
 
Device Therapies for Stroke Prevention in Atrial Fibrillation  
 
With the aging population, atrial fibrillation (AF) is the most commonly occurring cardiac arrhythmia requiring 
medical attention. Strategies for stroke prevention in AF have mostly centered on anticoagulation therapies. 
Newer anticoagulants such as dabigatran, apixaban, and rivaroxaban have proven to be at least equivalent to 
warfarin and potentially provide more reliable anticoagulation; however, the risk for bleeding complications still 
remains. Device-based alternatives for stroke prevention are, thus, appealing in patients at high risk for bleeding. 
Several devices are now in use including the Amplatzer left atrial appendage occlude (St. Jude Medical), the 
Watchman closure device (Aritech, Inc.), and the Lariat device (Sentre HEART). Hussein et al. present a 
comprehensive review of each device, focusing on patient selection and device delivery [54].  
 
Novel Stent Platforms  
 
Coronary stents have evolved significantly over time with changes in polymer, strut thickness, type of drug 
delivered, and the pharmacokinetics of drug delivery with the goal of reducing stent thrombosis and restenosis. 
Current second generation drug-eluting stents, while performing much better in both regards, have not fully 
eliminated in-stent restenosis and are plagued by late stent thrombosis when re-endothelialization of the metal 
scaffold is not complete. Drug-eluting bioresorbable scaffolds have the potential to address both of these issues. 
Porcine models have been used to develop a first generation magnesium BVS that is now under investigation in 
the large multicenter DREAMS-2 trial. Magnesium scaffolds may demonstrate a balance between suppression 
of vascular smooth muscle cell proliferation and enhancement of endothelial cell proliferation resulting in less 
neointimal growth and return of a normal endothelium. Interest in polymeric, as opposed to metal scaffolds, is 
also attractive as there may be fewer corrosion products deposited in the artery wall. However, increased strut 
thickness may impair deliverability and delayed resorption may impair their potential benefits on vascular 
biology. The ABSORB II and RESTORE II trials are now underway to test this platform type in a large clinical 
trial. To date, bioresorbable scaffolds have been studied only in elective PCI and their ability to reduce the need 
for prolonged dual antiplatelet therapy is unclear [55]. 
 
 
Antiplatelet Therapy Optimization: from Inflammation to Acute Coronary Syndrome 
 
The Journal published a special issue dedicated to the role of platelets from the onset of vascular atherosclerosis 
to acute coronary syndromes (ACS) [56–60]. The heterogeneity in response to current antiplatelet regimens with 
related clinical implications has been described in the following clinical settings [61–64]: (a) an impaired 
response to clopidogrel has been observed under conditions mimicking the hypothermic state of the comatose 
patients after ACS undergoing percutaneous coronary interventions (PCI), [62] (b) difficult therapeutic 
management with related increased bleeding risk in patients under chronic anticoagulation treated with PCI [60], 
(c) challenges of bridging antiplatelet therapy in patients requiring cardiac and noncardiac surgery [64], and (d) 
the gender differences in antiplatelet treatments and responses [65]. Future areas of investigations have been 
proposed in novel antiplatelet agents able to potently and safely inhibit platelet reactivity [66, 67]. Ridogrel and 
picotamide are novel inhibitors of the thromboxane (Tx) A2 pathway that promise to overcome the limitations 
of aspirin (the most widely used inhibitor of TxA2 synthesis) in blocking the isoprostanes. These novel 
inhibitors might prove particularly useful in selected patients like those with diabetes. Finally, a novel 
pharmacomechanical strategy based on the use of transradial access site and bivalirudin infusion has been 
proposed at the time of PCI for ACS patients in the MATRIX trial [68]. The MATRIX trial showed that radial 
as compared with femoral access reduced net adverse clinical events, through a reduction in major bleeding and 
all-cause mortality [69], while no significant differences were observed with bivalirudin as compared with 
unfractionated heparin [70].  
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